Global Infertility Drugs Market to Reach US$ 6.0 Billion by 2032, Propelled by the Rising Incidences of Infertility and Miscarriage

September 07, 2022 | Healthcare

The latest report by IMARC, titled “Infertility Drugs Market Report by Drug Class (Gonadotropin, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Biguanides, and Others), Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), End User (Male, Female), and Region 2024-2032”, finds that the global infertility drugs market reached a value of US$ 3.9 Billion in 2023. Infertility drugs refer to medications prescribed to treat infertility and improve the reproductive health of an individual. They are either injected or consumed orally. Some of the commonly available infertility drugs include aromatase inhibitors, gonadotrophins, selective estrogen receptor modulators (SERMs), ovulatory stimulants, biguanides, tricyclic antidepressants, and dopamine agonists. These drugs assist by stimulating ovulation and follicle development of the ovary in women while restoring testosterone levels in men and improving the quality of their sperm. In recent years, infertility drugs have gained momentum among couples who are unable to conceive.

Global Infertility Drugs Market Trends:

One of the primary factors driving the market is the rising incidences of infertility and miscarriage. Additionally, the increasing number of individuals diagnosed with thyroid, polycystic ovarian syndrome (PCOS), diabetes, and menopausal disorders due to the hectic lifestyle and stress is creating a positive market outlook. Other than this, the declining fertility rates due to unhealthy habits, such as a rise in the consumption of drugs, alcohol and smoking, are leading to an increase in the adoption rate of these medications. Besides this, extensive research and development (R&D) activities to introduce infertility drugs with better efficacy, lower dosage requirement, and lesser side effects are creating a positive market outlook. Other growth-inducing factors include enhancing health infrastructure, increasing consumer expenditure, rising demand for generic medicines, rapid urbanization, and technological upgradations. Looking forward, IMARC Group expects the market value to reach US$ 6.0 Billion by 2032, expanding at a CAGR of 4.7% during the forecast period (2024-2032).

Market Summary:

Based on the drug class, the market has been divided into gonadotropin, aromatase inhibitors, selective estrogen receptor modulators (SERMs), biguanides, and others.
On the basis of the route of administration, the market has been segregated into oral, intravenous, subcutaneous, and intramuscular.
Based on the distribution channel, the market has been segmented into hospital pharmacies, retail pharmacies, and others.
On the basis of the end user, the market has been bifurcated into males and females.
Region-wise, the market has been classified into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
The competitive landscape of the market has also been analyzed, with some of the key players being Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., and Theramex HQ UK Limited.

Report Scope:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Billion
Segment Coverage	Drug Class, Route of Administration, Distribution Channel, End User, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Theramex
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter : @imarcglobal

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Infertility Drugs Market to Reach US$ 6.0 Billion by 2032, Propelled by the Rising Incidences of Infertility and Miscarriage

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.